Drugmaker Biogen is pulling the plug on its controversial Alzheimer’s drug Aduhelm, following disappointing gross sales. It had been anticipated to be a blockbuster product.
MARY LOUISE KELLY, HOST:
A drugmaker is pulling the plug on an Alzheimer’s remedy that was as soon as anticipated to be a blockbuster. NPR’s Sydney Lupkin reviews on what occurred and what it might imply for sufferers.
SYDNEY LUPKIN, BYLINE: Aduhelm was imagined to be an enormous deal. That is as a result of the drug cleared sticky clumps of protein known as amyloid from the brains of sufferers with Alzheimer’s illness. Of the 2 massive research of Aduhelm submitted to the Meals and Drug Administration, one discovered that the drug delayed the lack of reminiscence and considering, whereas the opposite discovered no clear profit. A panel of specialists advising the company really helpful towards approval, however the company did it anyway in 2021 with a catch. Biogen, the drug’s maker, needed to do extra analysis to verify Aduhelm labored and get the examine accomplished by 2030. Now Biogen says it could not discover a companion or financing to assist pay for the expensive confirmatory examine, so it is reducing its losses and specializing in its different FDA-approved Alzheimer’s drug known as Leqembi. Dr. Aaron Kesselheim from Harvard was one in all three FDA advisers who resigned in protest over the Aduhelm approval.
AARON KESSELHEIM: The truth that within the intervening three-plus years that there was no extra knowledge that is come out that urged something constructive about this drug is an indicator to me that the advisory committee was appropriate in assessing this drug didn’t have good proof and mustn’t have been accepted.
LUPKIN: Aduhelm by no means took off. Biogen initially set its value at $56,000 a yr, however demand was so weak the corporate slashed the value in half just a few months later. Medicare additionally restricted protection for Aduhelm to sufferers who had been in medical trials. Nonetheless, Biogen’s determination to withdraw Aduhelm was sudden. Heather Snyder from the Alzheimer’s Affiliation says sufferers had been nonetheless being enrolled within the confirmatory examine when Biogen made its announcement. However she says there is a silver lining.
HEATHER SNYDER: The approval of Aduhelm was a landmark occasion that basically supplied hope for therefore many people which can be or had been dwelling with early Alzheimer’s and their households.
LUPKIN: And different experimental Alzheimer’s medicine are transferring ahead within the pipeline. Biogen says sufferers at the moment taking Aduhelm can have entry to it till November 1, however sufferers taking the drug in medical trials will lose entry Might 1. Biogen had licensed the drug from a Swiss biotech known as Neurimmune. Neurimmune says it should proceed to work on the drug and goals to hunt approval for a model that’s given by injection as an alternative of infusion.
Sydney Lupkin, NPR Information.
(SOUNDBITE OF MUSIC)
Copyright © 2024 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content is probably not in its last kind and could also be up to date or revised sooner or later. Accuracy and availability might range. The authoritative report of NPR’s programming is the audio report.
